Yes, milrinone is an inotrope, meaning it strengthens the heart’s contractions. But calling it “just” an inotrope undersells what it does. Milrinone also relaxes blood vessels, which is why clinicians often classify it as an “inodilator,” a drug that combines inotropic and vasodilator effects in a single agent. It is approved for short-term intravenous treatment of acute decompensated heart failure.
How Milrinone Works Inside Heart Cells
Milrinone belongs to a class of drugs called PDE3 inhibitors. To understand what that means in plain terms: your heart cells use a signaling molecule called cyclic AMP (cAMP) to regulate how forcefully they contract. An enzyme called PDE3 normally breaks down cAMP, keeping contractions in check. Milrinone blocks that enzyme, so cAMP levels rise and the heart muscle gets a stronger signal to contract.
That elevated cAMP triggers two things simultaneously. First, it increases the amount of calcium flowing into heart muscle cells and released from internal stores. Calcium is the mineral that physically drives muscle contraction, so more calcium means a more powerful squeeze during each heartbeat, improving the heart’s pumping ability. Second, cAMP speeds up the reabsorption of calcium after each contraction, which helps the heart relax more fully between beats. This dual action improves both the pumping phase and the filling phase of the cardiac cycle.
Why It’s Called an Inodilator, Not Just an Inotrope
Unlike some other heart-strengthening drugs, milrinone doesn’t work only on the heart. It relaxes smooth muscle in blood vessel walls throughout the body and in the lungs. Research published in Circulation demonstrated that milrinone has “both vasodilator and inotropic properties” and should not be considered a purely inotropic agent.
In patients with severe heart failure, a single intravenous dose of milrinone produced a meaningful set of changes: cardiac output increased by roughly 42%, resistance in the lung’s blood vessels dropped by about 31%, and pressure in the pulmonary arteries fell by 12%. These effects kicked in within 5 to 10 minutes and lasted at least 20 minutes. Pulmonary wedge pressure, a measure of how backed up fluid is in the lungs, also dropped significantly. This combination of stronger pumping and lower resistance is what makes milrinone particularly useful when the heart is failing and the body’s blood vessels are clamped down tight.
How It Differs From Dobutamine
The other common inotrope used in heart failure is dobutamine, which works by stimulating beta receptors on heart cells. This distinction matters in practice. Many heart failure patients take beta-blocker medications, which deliberately block those same receptors. If you give dobutamine to someone on a beta-blocker, the two drugs essentially compete, and dobutamine becomes less effective.
Milrinone bypasses beta receptors entirely. Because it works downstream at the enzyme level, beta-blockers don’t blunt its effect. Data from the Journal of the American Heart Association showed that patients receiving milrinone were nearly twice as likely to be on a beta-blocker compared to those receiving dobutamine (46% versus 24%). This makes milrinone the more practical choice when a patient’s existing medications include beta-blockers.
What Milrinone Is Used For
The FDA-approved use is narrow: short-term intravenous treatment of acute decompensated heart failure, the kind of crisis where the heart suddenly can’t pump enough blood to meet the body’s needs. In this setting, milrinone serves as a bridge, supporting the heart while other treatments take effect or while a patient awaits a more definitive intervention like a heart transplant.
Its ability to lower pulmonary vascular resistance makes it especially valuable for right-sided heart failure and pulmonary hypertension. In patients being evaluated for heart transplantation, elevated lung pressures are a risk factor for post-transplant complications. A study of 27 patients with severe heart failure and high pulmonary vascular resistance found that a single bolus of milrinone decreased that resistance in every patient tested, and the effect was well tolerated even in people with low blood pressure to begin with.
How It’s Given
Milrinone is delivered through an IV, either in a hospital or, for some patients with advanced heart failure, through a home infusion setup. A loading dose exists on paper, but in common practice it is often skipped because it can cause a sudden drop in blood pressure.
The typical maintenance infusion starts at 0.1 micrograms per kilogram per minute and can be titrated up based on response, with a usual range of 0.125 to 0.35 micrograms per kilogram per minute and a maximum of 0.75. Because milrinone has a relatively long half-life of about 2.3 to 2.4 hours in heart failure patients, dose adjustments are generally spaced 2 to 4 hours apart to allow the drug to reach a steady level. About 90% of the drug is cleared through the kidneys within eight hours, so patients with severe kidney impairment need lower doses since the drug lingers longer in their system.
Side Effects to Watch For
The two main concerns with milrinone are low blood pressure and abnormal heart rhythms. In clinical trials, sustained hypotension occurred in about 10.7% of patients on milrinone compared to 3.2% on placebo. Atrial arrhythmias, irregular rhythms originating in the upper chambers of the heart, were also more common: 4.6% versus 1.5% with placebo. These risks are why milrinone is used under close monitoring, typically with continuous heart rhythm and blood pressure tracking.
The blood pressure drop stems directly from the drug’s vasodilator properties. In patients who already have borderline low pressure, clinicians weigh whether the benefit of improved cardiac output outweighs the risk of pushing pressure too low. The pulmonary hypertension study noted that milrinone had no significant effect on heart rate or systemic arterial pressure at the doses tested, but individual responses vary, and higher or prolonged dosing increases the risk.